VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. According to the company, its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement are significant for the biotechnology industry and for investors. By adopting FDA-aligned NAMs, VERAXA aims to streamline preclinical development, potentially bringing therapies to patients faster while lowering costs. The reduction in animal testing also addresses growing ethical and regulatory pressures to minimize animal use in research. If successful, this strategy could serve as a model for other companies seeking to modernize their preclinical workflows.
For more details, the full press release is available at https://ibn.fm/9YRJw. The latest news and updates relating to VRXA can be found in the company's newsroom at https://ibn.fm/VRXA. The original release was published on www.newmediawire.com.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). Its BiTAC format is a registered trademark of VERAXA Biotech GmbH.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Undue reliance should not be placed on these statements when making an investment decision. For full terms of use and disclaimers, please visit https://IBN.ai/Disclaimer.
